Health and Healthcare

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

577 Articles

Chris Lange | Jul 3, 2016 at 7:38 AM EDT

How Major Pharma Is Faring After the Brexit

The broad markets are recovering in the wake of the Brexit and it really appears to be one big head…

Chris Lange | Jun 27, 2016 at 8:11 AM EDT

Short Sellers Increase Bets Against Major Pharmaceutical Stocks

The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a…

Chris Lange | Jun 10, 2016 at 8:05 AM EDT

Major Pharma Has Short Sellers on the Run

The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | Jun 6, 2016 at 1:40 PM EDT

How Credit Suisse Views Major Pharma After ASCO

The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two…

Chris Lange | Jun 2, 2016 at 10:50 AM EDT

Merrill Lynch Picks ASCO Winners

Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology…

Chris Lange | May 29, 2016 at 10:15 AM EDT

Key Movers to Look for Ahead of ASCO

The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers…

Lee Jackson | May 25, 2016 at 10:05 AM EDT

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue…

Chris Lange | May 25, 2016 at 8:15 AM EDT

Short Sellers Take Mixed Stance on Major Pharma

The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | May 19, 2016 at 10:20 AM EDT

8 Stocks on the Move After ASCO Cancer Abstracts

ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or…

Chris Lange | May 11, 2016 at 8:45 AM EDT

Major Pharma Short Interest Continues to Recede

The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical…

Chris Lange | Apr 28, 2016 at 9:20 AM EDT

Bristol-Myers Squibb Offers Up Solid Earnings Beat and Lifts Guidance

Bristol-Myers Squibb released better-than-expected first-quarter financial results before the markets opened on Thursday.

Chris Lange | Apr 27, 2016 at 9:15 AM EDT

Major Pharma Short Interest Remains Mixed, With 1 Massive Drop

The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Chris Lange | Apr 12, 2016 at 9:50 AM EDT

Short Sellers Become More Selective in Major Pharma

The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Lee Jackson | Mar 30, 2016 at 11:05 AM EDT

Top Dividend-Paying Pharmaceutical Stocks Rated Buy by Analysts

Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the…

Chris Lange | Mar 15, 2016 at 9:25 AM EDT

Jefferies Top Drug Stocks for the Rest of 2016

For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made…

1 … 22 23 24 25 26 … 39

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

How Major Pharma Is Faring After the Brexit

Short Sellers Increase Bets Against Major Pharmaceutical Stocks

Major Pharma Has Short Sellers on the Run

How Credit Suisse Views Major Pharma After ASCO

Merrill Lynch Picks ASCO Winners

Key Movers to Look for Ahead of ASCO

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Short Sellers Take Mixed Stance on Major Pharma

8 Stocks on the Move After ASCO Cancer Abstracts

Major Pharma Short Interest Continues to Recede

Bristol-Myers Squibb Offers Up Solid Earnings Beat and Lifts Guidance

Major Pharma Short Interest Remains Mixed, With 1 Massive Drop

Short Sellers Become More Selective in Major Pharma

Top Dividend-Paying Pharmaceutical Stocks Rated Buy by Analysts

Jefferies Top Drug Stocks for the Rest of 2016

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

How Major Pharma Is Faring After the Brexit

Short Sellers Increase Bets Against Major Pharmaceutical Stocks

Major Pharma Has Short Sellers on the Run

How Credit Suisse Views Major Pharma After ASCO

Merrill Lynch Picks ASCO Winners

Key Movers to Look for Ahead of ASCO

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Short Sellers Take Mixed Stance on Major Pharma

8 Stocks on the Move After ASCO Cancer Abstracts

Major Pharma Short Interest Continues to Recede

Bristol-Myers Squibb Offers Up Solid Earnings Beat and Lifts Guidance

Major Pharma Short Interest Remains Mixed, With 1 Massive Drop

Short Sellers Become More Selective in Major Pharma

Top Dividend-Paying Pharmaceutical Stocks Rated Buy by Analysts

Jefferies Top Drug Stocks for the Rest of 2016

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do